Genor Biopharma Holdings Limited
HKEX:6998.HK
1.65 (HKD) • At close November 14, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Assets: | ||||||
| Current Assets: | ||||||
| Cash & Cash Equivalents
| 1,165.481 | 1,588.705 | 2,200.641 | 2,929.743 | 253.52 | 125.158 |
| Short Term Investments
| 0 | 0 | 0 | 0 | 0 | 0 |
| Cash and Short Term Investments
| 1,165.481 | 1,588.705 | 2,200.641 | 2,929.743 | 253.52 | 125.158 |
| Net Receivables
| 0 | 0 | 0 | 0 | 0 | 0.581 |
| Inventory
| 5.667 | 47.404 | 49.653 | 31.465 | 25.269 | 25.24 |
| Other Current Assets
| 69.975 | 84.044 | 136.284 | 140.199 | 69.451 | 531.491 |
| Total Current Assets
| 1,241.123 | 1,720.153 | 2,386.578 | 3,101.407 | 348.24 | 682.47 |
| Non-Current Assets: | ||||||
| Property, Plant & Equipment, Net
| 60.137 | 205.217 | 223.367 | 229.163 | 224.696 | 241.307 |
| Goodwill
| 17.819 | 21.753 | 21.753 | 21.753 | 21.753 | 0 |
| Intangible Assets
| 92.28 | 141.455 | 149.29 | 135.183 | 72.564 | 16.033 |
| Goodwill and Intangible Assets
| 110.099 | 163.208 | 171.043 | 156.936 | 94.317 | 16.033 |
| Long Term Investments
| 0 | 0 | 0 | 0 | 0 | 0 |
| Tax Assets
| 0 | 6.913 | 5.732 | 5.643 | 0.68 | 0 |
| Other Non-Current Assets
| 35.518 | 19.6 | 76.121 | 80.3 | 64.902 | 47.851 |
| Total Non-Current Assets
| 205.754 | 394.938 | 476.263 | 472.042 | 384.595 | 305.191 |
| Total Assets
| 1,446.877 | 2,115.091 | 2,862.841 | 3,573.449 | 732.835 | 987.661 |
| Liabilities & Equity: | ||||||
| Current Liabilities: | ||||||
| Account Payables
| 152.214 | 132.158 | 129.666 | 91.732 | 103.363 | 30.868 |
| Short Term Debt
| 3.231 | 6.763 | 37.301 | 15.045 | 12.412 | 8.958 |
| Tax Payables
| 1.844 | 2.237 | 3.505 | 2.351 | 0.638 | 0.331 |
| Deferred Revenue
| 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities
| 72.236 | 119.237 | 142.716 | 139.602 | 243.711 | 59.502 |
| Total Current Liabilities
| 229.525 | 260.395 | 313.188 | 248.73 | 360.124 | 99.659 |
| Non-Current Liabilities: | ||||||
| Long Term Debt
| 3.924 | 21.823 | 20.107 | 16.014 | 29.351 | 35.792 |
| Deferred Revenue Non-Current
| 0 | 13.984 | 18.149 | 22.658 | 23.647 | 28.606 |
| Deferred Tax Liabilities Non-Current
| 0 | 12.439 | 13.282 | 14.125 | 14.968 | -28.606 |
| Other Non-Current Liabilities
| 22.728 | 1.232 | 36.435 | 71.58 | 117.9 | 0 |
| Total Non-Current Liabilities
| 26.652 | 49.478 | 56.542 | 87.594 | 147.251 | 64.398 |
| Total Liabilities
| 256.177 | 309.873 | 369.73 | 336.324 | 507.375 | 164.057 |
| Equity: | ||||||
| Preferred Stock
| 0 | 1,452.204 | 1,409.824 | 1,426.445 | 209.35 | 0 |
| Common Stock
| 0.069 | 0.069 | 0.068 | 0.067 | 0.039 | 0.015 |
| Retained Earnings
| -6,790.336 | -6,115.974 | -5,385.76 | -4,520.536 | -1,493.434 | -971.352 |
| Accumulated Other Comprehensive Income/Loss
| -1,413.572 | -1,452.204 | -1,409.824 | -1,426.445 | -209.35 | 331.312 |
| Other Total Stockholders Equity
| 9,392.653 | 9,370.587 | 9,285.705 | 9,180.967 | 1,921.731 | 1,463.629 |
| Total Shareholders Equity
| 1,188.814 | 1,802.478 | 2,490.189 | 3,234.053 | 218.986 | 823.604 |
| Total Equity
| 1,190.7 | 1,805.218 | 2,493.111 | 3,237.125 | 225.46 | 823.604 |
| Total Liabilities & Shareholders Equity
| 1,446.877 | 2,115.091 | 2,862.841 | 3,573.449 | 732.835 | 987.661 |